|Epigentek Releases a Series of Histone H3-K4 Demethylase Activity and Inhibition Assay Kits
|NEW YORK, Nov 13 -- Epigentek Group Inc. announced that it released the EpiQuik (TM) histone H3-K4 demethylase activity/inhibition assay kit series (http://www.epigentek.com/catalog/histone-demethylase-assay-c-23_57.html).
Histone H3-K4 demethylases have been found to play an important role in cancer development. The kit series offer a flexible choice of different kits used for measuring activity/inhibition of total H3-K4 histone demethylases (LSD1 and JARIDs), or LSD1 activity/inhibition using tissue/cell lysate and for screening LSD1 inhibitors using purified enzymes.
These kits allow entire assays to be completed within just three hours in microplate format, which would provide a high throughput screening tool for discovering inhibitors of histone H3-K4 specific demethylases as the therapeutics agents.
About Epigentek Group Inc.
Epigentek Group Inc. is a biotechnology company that focuses on developing and providing innovative technology and products as a complete and systematic solution for epigenetics-related research and drug discovery. The company has developed a comprehensive portfolio of more than 400 proprietary products that are used all around the world by esteemed academia, leading pharmaceuticals, and cutting edge biotechnology companies. These unique products are specifically designed to make assays significantly more simple, fast, convenient and efficient than conventional methods. The company, particularly emphasizing speed and effectiveness in its technologies, continues to focus on epigenetic innovation and to extensively develop and enhance its product portfolio. Visit our website at www.epigentek.com.